The ATCG database showed that 10% of cases profiled show gene amplification for CERS2 in bladder cancer (data obtained through cBioPortal [61]), and regarding gene transcription, the expression is slightly higher in cancer samples (Log2 foldchange 0.2, with a p value of 0.025) among 432 samples (404 tumor vs. 28 non-tumor, data obtained through GEPIA2 [62]). Here, CERS2 is linked to urinary bladder carcinoma.